Entera Bio Ltd. (ENTX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing first-in-class oral tablet formats of peptides or protein replacement therapies using its proprietary N-Tab® platform. The company is incorporated in Israel and listed on the Nasdaq Capital Market. Its primary focus is on underserved chronic conditions, specifically osteoporosis (EB613), hypoparathyroidism (EB612), and obesity/metabolic disorders (EB618).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $42,000 |
| Net Loss | $(3,505,000) | $(2,567,000) |
| Operating Loss | $(3,539,000) | $(2,563,000) |
| Research & Development (R&D) Expenses | $2,251,000 | $1,123,000 |
| General & Administrative (G&A) Expenses | $1,288,000 | $1,440,000 |
| Cash and Cash Equivalents | $4,137,000 | $12,573,000 |
| Restricted Cash | $7,790,000 | $7,775,000 |
| Total Cash & Restricted Cash | $11,927,000 | $20,348,000 |
| Accumulated Deficit | $(128,871,000) | $(116,494,000) |
| Net Cash Used in Operating Activities | $(3,090,000) | $(1,404,000) |
Note: The company reported no debt obligations other than operating lease liabilities ($448,000 total).
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero from $42,000 in Q1 2025, as the prior period included revenue from a completed research services agreement.
- Increased R&D Spend: R&D expenses increased by 100% ($1.1 million increase) year-over-year. This was driven by a $0.5 million increase for the Phase 1 safety and PK bridging study of the Next Generation of EB613 and a $0.5 million increase related to collaboration programs with OPKO (EB618 and EB612).
- Net Loss Expansion: Net loss increased by 37% to $3.5 million, primarily due to higher operating expenses.
- Cash Burn: Net cash used in operating activities increased to $3.1 million from $1.4 million. Total cash and restricted cash decreased by approximately $8.4 million during the quarter.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management believes existing cash resources, combined with proceeds from a subsequent private placement (see below), will fund operations through the first quarter of 2027. However, the company explicitly states that its current capital resources do not include the funds required to fully fund the proposed Phase 3 program for EB613. The filing raises substantial doubt about the company's ability to continue as a going concern absent additional financing.
Recent Developments (Subsequent Events): In April 2026, the company completed a private placement raising approximately $10.0 million through the sale of units consisting of ordinary shares, pre-funded warrants, and warrants. Proceeds are intended to support the Phase 3 registrational study of EB613 and general working capital.
Key Risks and Contingencies:
- Geopolitical Instability: The company faces significant risks due to the ongoing conflict in the Middle East (Israel-Hamas, Hezbollah, Iran). While current operations in Israel are largely unaffected, escalation could disrupt research personnel, supply chains, and operations.
- Regulatory Uncertainty: Success depends on FDA approval for EB613 (osteoporosis) and other candidates. The company submitted a clinical amendment for the EB613 Phase 3 protocol in February 2026.
- Liquidity Risk: Continued reliance on equity financing or strategic partnerships to fund clinical trials. Failure to secure funding could delay or terminate development programs.
Investor Verification Checklist
- Runway Validation: Verify if the $10 million raised in April 2026 is sufficient to reach the planned Phase 3 initiation for EB613 in H2 2026, given the stated need for additional capital to complete the study.
- EB613 Phase 3 Timeline: Confirm the status of FDA feedback on the clinical amendment submitted in February 2026 and the actual initiation date of the Phase 3 study.
- OPKO Collaboration Terms: Review the specific cost-sharing and milestone obligations under the Amended and Restated Collaboration Agreement with OPKO regarding EB612 and EB618.
- Geopolitical Impact: Monitor the stability of the ceasefire agreements in the Middle East and their potential impact on the company's Israeli-based workforce and facilities.
- Dilution Risk: Assess the dilution impact of the April 2026 private placement (7.9 million units issued) and the potential exercise of outstanding warrants.